An Anti-Cd154 Domain Antibody Prolongs Graft Survival and Induces Foxp3+iTreg in the Absence and Presence of CTLA-4 Ig

American Journal of Transplantation - United Kingdom
doi 10.1111/ajt.12417
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

Dose-Dependent Effect of Anti-Ctla-4 on Survival in Sepsis

Shock
Critical CareEmergency MedicineIntensive Care Medicine
2011English

The CTLA-4 X OX40 Bispecific Antibody ATOR-1015 Induces Anti-Tumor Effects Through Tumor-Directed Immune Activation

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Interleukin-13 but Not Interleukin-4 Prolongs Eosinophil Survival and Induces Eosinophil Chemotaxis.

Internal Medicine
Internal MedicineMedicine
1997English

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Clinical Cancer Research
Cancer ResearchOncology
2019English

Conformational Preference of Serogroup B Salmonella O Polysaccharide in Presence and Absence of the Monoclonal Antibody Se155–4

Journal of Physical Chemistry B
SurfacesTheoretical ChemistryMaterials ChemistryFilmsMedicineCoatingsPhysical
2016English

Allogeneic Hematopoietic Chimerism in Mice Treated With Sublethal Myeloablation and Anti-Cd154 Antibody: Absence of Graft-Versus-Host Disease, Induction of Skin Allograft Tolerance, and Prevention of Recurrent Autoimmunity in Islet-Allografted NOD/Lt Mice

Blood
BiochemistryImmunologyCell BiologyHematology
2000English

Improved Survival With T Cell Clonotype Stability After Anti-Ctla-4 Treatment in Cancer Patients

Science Translational Medicine
Medicine
2014English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy